Navigation Links
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio™(*)) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity
Date:10/5/2011

nomide compared to placebo. No serious or opportunistic infections and no deaths occurred in trial participants treated with teriflunomide.  The proportion of participants who discontinued the study medication because of disease progression was significantly smaller in the group receiving the 14mg of teriflunomide than in the placebo group (p=0.02). Malignancies were reported in three participants in the placebo group and one in the teriflunomide 14mg group.

Teriflunomide adverse events were usually of mild to moderate intensity, managed with existing therapies and rarely led to treatment discontinuation. The most common were diarrhea, nausea, liver enzyme increases (that were mainly mild and asymptomatic with no dose effect) and mild hair thinning/decreased hair density. In general, diarrhea, nausea and alopecia, were mild to moderate, transient, and infrequently led to treatment discontinuation.

About Teriflunomide
Teriflunomide is an immunomodulatory, disease-modifying oral drug with anti-inflammatory properties, and is under investigation for the treatment of MS. Teriflunomide blocks the proliferation and functioning of activated T and B  lymphocytes - which are thought to be especially damaging in MS - by selectively and reversibly inhibiting a critical mitochondrial enzyme. Slowly dividing or resting lymphocytes are unaffected by teriflunomide, leaving the immune system's response to infection uncompromised. With nine years of continuous use in a Phase II extension, teriflunomide has the longest clinical experience of any investigational oral MS therapy. In addition to the TEMSO trial, two other Phase III trials, TOWER and TENERE, are ongoing in people with RMS. A Phase III study, TOPIC, is also underway in early MS or CIS (clinically isolated syndrome). Teriflunomide is also being evaluated as an adjunct therapy to interferon-beta in the Phase III TERACLES trial.

(*) Aubagio™ is the registered name submitted to
'/>"/>

SOURCE Sanofi; Genzyme
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger
2. Positive Phase III Data on Bayers Investigational Drug Radium-223 Chloride Show Significant Increase in Overall Survival
3. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
4. Bayer to Present New Data Evaluating Investigational Oncology Compounds at 2011 ECCO-ESMO Congress
5. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
6. FDA Grants Fast Track Designation to Bayers Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
7. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
8. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
9. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
10. Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Associations 71st Annual Scientific Sessions
11. Morphotek, Inc. Announces That Two Investigational Drugs Have Received Orphan Drug Designations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014  Rebiotix Inc. announced this morning that results of ... RBX2660 (microbiota suspension) will be presented in two posters and ... Philadelphia from October 8-12. ... session on Thursday, October 9, 2014: Poster: RBX2660 ... Interim Analysis of the PUNCH-CD Phase 2 Safety Study ...
(Date:9/17/2014)... 17, 2014  Bayer HealthCare will present data on ... th Annual Meeting, which takes place September 18-20 ... which will be shared through poster presentations, showcase Bayer,s ... Data will be presented in a scientific forum. ... in hemophilia A patients, Bayer is maintaining its commitment ...
(Date:9/17/2014)... September 17, 2014 According to ... Component (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU), by ... Wellness), and by Geography - Global Forecast to 2020", ... market is expected to reach $56.50 Billion by 2020, ... 2020. Browse 235 market data Tables and ...
Breaking Medicine Technology:PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4
... (Nasdaq: ENDP ) today announced that it will present ... 2011 at 3:45 p.m. ET.  Dr. Ivan Gergel executive vice president ... programs. The presentation will be webcast live and can ... investors section.   About Endo ...
... nation,s leading retail pharmacy, brings its "To Your Health" ... Texas. The program will provide free preventive health screenings ... through November as a way to help citizens determine ... a path to better health. (Logo: ...
Cached Medicine Technology:CVS/pharmacy Debuts the 'To Your Health' Program in Dallas and Fort Worth Texas, Bringing More Than 80 Free Health Screening Events to the Community 2CVS/pharmacy Debuts the 'To Your Health' Program in Dallas and Fort Worth Texas, Bringing More Than 80 Free Health Screening Events to the Community 3
(Date:9/18/2014)... Angeles, CA (September 18, 2014) Cardiovascular disease is ... cholesterol plays a major role in accelerating its ... a treatment to decrease cholesterol-carrying lipoproteins such as ... harmful. A new study, out today in the ... finds that rosuvastatin may be more effective among ...
(Date:9/18/2014)... 2014 On August 23, the ... with the Distinguished Service Award for his contributions to ... 2014 National Basketball Retired Players Association (NBRPA) Legends World ... the Chicago Bulls in 1977, Glenn would go on ... Knicks, the Atlanta Hawks, and the Milwaukee Bucks throughout ...
(Date:9/18/2014)... September 18, 2014 One Week Kitchens will ... the Bloomsburg Fair beginning this Saturday. Their display will be ... great example of the products and design services that are ... various countertops for fair-goers to see. This display won ‘Most ... earlier this year and really is something to see. ...
(Date:9/18/2014)... September 18, 2014 Demand for competency-based ... seek more efficient routes to job placement and employers ... not have come at a better time as the ... supply. , Working in collaboration with employers, career educators ... approach to CBE implementation and direct assessment ...
(Date:9/18/2014)... 2014 SpineFrontier is expanding its ... partners in Less Exposure Surgery Technology by hiring ... an extensive education curriculum and trained sales representatives ... in Organizational Leadership, and has educated and trained ... Bringing her to the team is a big ...
Breaking Medicine News(10 mins):Health News:The HearStrong Foundation Recognizes Mike “Stinger” Glenn with the Distinguished Service Award at the 2014 Legends World Sports Conference 2Health News:The HearStrong Foundation Recognizes Mike “Stinger” Glenn with the Distinguished Service Award at the 2014 Legends World Sports Conference 3Health News:One Week Kitchens Taking Display to Bloomsburg Fair 2Health News:Wonderlic Unites Employers, Career Educators and Competency-Based Education Experts to Help Narrow Skills Gap 2Health News:SpineFrontier Inc. Makes Bold Move to Expand Its Internal Training Team to Collaborate With The LESSociety’s Less Exposure Surgery® University To Educate Surgeons. 2
... CHARLESTON, W.Va., Jan. 28 Author Ernie Vecchio ... Soul,s Intent" (published by iUniverse -- http://www.iuniverse.com ... experiences, findings, and insights while treating individuals recovering ... with trauma patients that when personality gets stripped ...
... diabetes, heart disease, developmental problems , , WEDNESDAY, Jan. 28 ... to harden plastics for consumer products such as baby ... body much longer than thought, a new study says. ... come from many different sources, not just food products, ...
... Security vendors gradually built a strong presence in ... the medical community. Technological advances and increasing applications ... staff coming to terms with inevitable compliance standards ... double-digit rates, the market looks highly lucrative over ...
... Foundation is,holding its Annual Fundraising Benefit this evening in ... Palace Hotel and serves as the showcase,for recent advances ... Benefit begins at 5 pm with a scientific overview ... of GRF,s Catalyst for a,Cure (CFC) consortium. A reception ...
... Jan. 28 The International Medical Interpreters Association ... structure for its organization. "Our revised bylaws do ... are unevenly distributed among different states and this ... Arocha, IMIA President.The organization will now have a ...
... REM Medical Corporation, a leader in innovative fatigue management ... Gordon Trucking, has chosen REM Medical as its provider ... will provide obstructive sleep apnea (OSA) diagnostic and treatment ... high probability of this serious sleep disorder. The ...
Cached Medicine News:Health News:'The Soul's Intent': An Interview with the Divine 2Health News:Controversial Chemical Lingers Longer in the Body: Study 2Health News:Controversial Chemical Lingers Longer in the Body: Study 3Health News:Frost & Sullivan Finds Compliance Requirements Drive the Healthcare Security Boom 2Health News:Frost & Sullivan Finds Compliance Requirements Drive the Healthcare Security Boom 3Health News:Glaucoma Research Foundation to Hold Annual Fundraising Benefit 2Health News:International Medical Interpreter Association Appoints IMIA State Representatives 2Health News:Gordon Trucking Begins Sleep Apnea Wellness Program with REM Medical Corporation 2
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride. 1.5% agararose...
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Inoculum Broth with Calcium Chloride and Phytone....
Medicine Products: